Revance Therapeutics (RVNC) News Today $3.02 -0.01 (-0.33%) (As of 03:09 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Revance Therapeutics (NASDAQ:RVNC) Given New $3.10 Price Target at MizuhoMizuho dropped their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating for the company in a report on Tuesday.December 10 at 8:32 AM | marketbeat.comCrown Labs Slashes Revance Therapeutics Takeover Price by 53%December 9 at 3:36 PM | marketwatch.comRevance agrees to lower take-private offer by Crown LabsDecember 9 at 3:36 PM | investing.comCrown Laboratories To Buy Revance For $3.10/Share In Amended And Restated Merger DealDecember 9 at 3:36 PM | markets.businessinsider.comRevance Therapeutics plunges after Crown Labs cuts takeover price in halfDecember 9 at 3:36 PM | seekingalpha.comRevance Therapeutics once again tries to go private with Crown Laboratories mergerDecember 9 at 3:36 PM | bizjournals.comRevance agrees to lower-priced buyout offer by Crown LaboratoriesDecember 9 at 9:12 AM | reuters.comCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementDecember 9 at 8:30 AM | prnewswire.comRevance Therapeutics Extends Offer Commencement Date in Merger AgreementDecember 9 at 2:05 AM | americanbankingnews.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Recommendation of "Hold" from AnalystsRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given a consensus rating of "Hold" by the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating and one has assigned a buy ratinDecember 7 at 4:29 AM | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of Revance Therapeutics in a research report on Wednesday. They set a "hold" rating for the company.December 4, 2024 | marketbeat.comWalleye Capital LLC Reduces Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Walleye Capital LLC decreased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 83.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 699,621 shares of the biopharmaceuticaDecember 3, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Extends Date for Commencement of Tender Offer with Buyer PartiesRevance Therapeutics, Inc. (RVNC) announced today in a current report filed with the U.S. Securities and Exchange Commission (SEC) that the company, alDecember 2, 2024 | americanbankingnews.comAstraZeneca (NASDAQ:AZN) vs. Revance Therapeutics (NASDAQ:RVNC) Head-To-Head SurveyDecember 1, 2024 | americanbankingnews.comRevance Therapeutics, Crown Labs Extend Tender Offer Start Deadline to Dec. 3 >RVNCNovember 29, 2024 | marketwatch.comHyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029November 29, 2024 | globenewswire.comRevance Therapeutics gains as Crown Labs further extends tender offerNovember 21, 2024 | msn.comAlpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Alpine Associates Management Inc. acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,162,861 shares of the biopharmaceutical companyNovember 20, 2024 | marketbeat.comBarclays Remains a Hold on Revance Therapeutics (RVNC)November 19, 2024 | markets.businessinsider.comLMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC)LMR Partners LLP acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,244,400 shares of the biopharmaceutical compNovember 18, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Monday. They set a "hold" rating for the company.November 18, 2024 | marketbeat.comRevance Therapeutics jumps after Crown Laboratories tender offer extended againNovember 13, 2024 | msn.comCautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties with Crown LaboratoriesNovember 13, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Revance Therapeutics (RVNC)November 12, 2024 | markets.businessinsider.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from AnalystsRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given an average rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. TheNovember 12, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCNovember 10, 2024 | prnewswire.comStockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)StockNews.com began coverage on shares of Revance Therapeutics in a research report on Sunday. They set a "hold" rating on the stock.November 10, 2024 | marketbeat.comRevance Therapeutics Reports Q3 Growth Amid Merger PlansNovember 9, 2024 | markets.businessinsider.comRevance withdraws previously provided guidanceNovember 8, 2024 | markets.businessinsider.comRevance Therapeutics sinks amid `going concern' disclosureNovember 8, 2024 | seekingalpha.comRevance Therapeutics' (RVNC) "Hold" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Revance Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Earns "Neutral" Rating from HC WainwrightHC Wainwright restated a "neutral" rating and set a $6.60 price target on shares of Revance Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNovember 7, 2024 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCNovember 2, 2024 | prnewswire.comLost Money on Revance Therapeutics, Inc. (RVNC)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyNovember 1, 2024 | stockhouse.comRevance Therapeutics (NASDAQ:RVNC) Stock, Insider Trading ActivityOctober 29, 2024 | benzinga.comRevance Therapeutics surges after Crown tender offer extended, settles with TeoxaneOctober 29, 2024 | msn.comRevance Therapeutics Sees Unusually High Options Volume (NASDAQ:RVNC)Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) was the recipient of unusually large options trading on Monday. Traders purchased 2,392 put options on the stock. This is an increase of approximately 144% compared to the typical daily volume of 981 put options.October 28, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Shares Gap Up - Still a Buy?Revance Therapeutics (NASDAQ:RVNC) Shares Gap Up - Should You Buy?October 28, 2024 | marketbeat.comRevance Shares Rise Premarket on Teoxane Settlement, Tender ExtensionOctober 28, 2024 | marketwatch.comRevance Therapeutics drops as deadline for Crown Lab tender set to expireOctober 25, 2024 | msn.comRevance Therapeutics (NASDAQ:RVNC) Shares Down 3.8% - Here's What HappenedRevance Therapeutics (NASDAQ:RVNC) Stock Price Down 3.8% - Here's WhyOctober 25, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCOctober 25, 2024 | prnewswire.comRevance Therapeutics, Crown Labs Again Extend Tender Offer DeadlineOctober 18, 2024 | marketwatch.comRevance Therapeutics (RVNC) Gets a Hold from Mizuho SecuritiesOctober 18, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCOctober 17, 2024 | prnewswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of InvestorsOctober 15, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of InvestorsOctober 15, 2024 | businesswire.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in SeptemberRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 9,540,000 shares, a growth of 25.0% from the September 15th total of 7,630,000 shares. Based on an average trading volume of 4,740,000 shares, the days-to-cover ratio is presently 2.0 days.October 15, 2024 | marketbeat.com Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Two men are working to save America (Ad) I’m back with a new exposé… The sequel to my documentary. Only this time, it’s not about two men destroying America… but two men trying to save it. Click here to see what is happening RVNC Media Mentions By Week RVNC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVNC News Sentiment▼0.110.67▲Average Medical News Sentiment RVNC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVNC Articles This Week▼134▲RVNC Articles Average Week Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRAX News Today ARDX News Today UPB News Today ANIP News Today INVA News Today ELVN News Today CALT News Today BCAX News Today OPK News Today COGT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVNC) was last updated on 12/10/2024 by MarketBeat.com Staff From Our PartnersTwo men are working to save America I’m back with a new exposé… The sequel to my documentary. Only this time, it’s not about two men destroyin...Porter & Company | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
